Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Overview
Date Founded

2014

Headquarters

60 Jubilee Avenue,Milton Park,Abingdon, Oxfordshire OX14 4RX

Type of Company

Public

Employees (Worldwide)

462

Industries

Biotechnology

Company Description

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Contact Data
Trying to get in touch with decision makers at Adaptimmune Therapeutics PLC? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer & Principal Accounting Officer

Chief Operating Officer

Chief Business Officer

Chief Patient Supply Officer

Chief Medical Officer

Vice President & Head, BioMarker Research & Development

Head, Autoimmune Group

Head of Process Development

Senior Director, Investor Relations

Board of Directors

Chairman at Zyngenia, Inc.

Co-Chair, Scientific Advisory Board at Amgen, Inc.

Treasurer at Boy Scouts of America - National Capital Area Council

General Partner at New Enterprise Associates, Inc.

Former Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc.

Former Non-Executive Director & Partner at MediGene AG

Chief Executive Officer at Adaptimmune Therapeutics PLC

Venture Partner at OrbiMed Advisors LLC

Chief Executive Officer & Director at Imvax, Inc.

Paths to Adaptimmune Therapeutics PLC
Potential Connections via
Relationship Science
You
Adaptimmune Therapeutics PLC
Owners & Shareholders
Details Hidden

MCM aims to generate an attractive risk-adjusted return by, investing the Master Fund’s assets in a concentrated portfolio of long and short positions, following the classic hedge fund model. Their strategy is to achieve this goal through maintaining a concentrated portfolio of long and short investments, over the long-term, driven by differentiating research into company fundamentals. The firm performs a fundamental bottom-up analysis to assess a company’s intrinsic value.

Details Hidden

New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements.

Details Hidden

PFM generally uses bottom-up analysis to identify trends, investment themes and core investment opportunities across asset classes and geographies in a wide range of investment instruments. The firm may invest in various industries or sectors, including, but not limited to, communications and media, consumer, energy, financials, healthcare, industrials, materials, technology and utilities. Their main investment strategies include diversified global and healthcare. PFM seeks to identify out- and under-performing companies that have the widest expectation gaps relative to consensus. In some cases, they may apply a catalyst-driven investment approach to express their fundamental view with respect to a company. PFM may also engage in top-down macro-economic analysis to identify opportunities, whether on a directional or relative value basis, across a wide range of global markets and investment instruments. They may consider economic, political and financial market conditions in seeking to identify attractive investment opportunities. The firm invests in and trades a wide range of investment instruments, including securities, options, ETFs, futures, currencies, derivatives, debt instruments and other assets that are financial instruments. They take both long and short positions in such investment instruments.

Recent Transactions
Details Hidden

Adaptimmune Therapeutics PLC issued USD American Depositary Shares

Details Hidden

Adaptimmune Therapeutics PLC issued USD American Depository Shares

Details Hidden

Adaptimmune Therapeutics PLC issued . USD American Depositary Shares

Transaction Advisors
Underwriter

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares

Auditor

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares

Legal Advisor

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares

Professional

Advised onAdaptimmune Therapeutics PLC issued USD American Depositary Shares

Advisors & Consultants
Legal Advisor

Partner, New York at Cooley LLP

Clients

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2020
Market Capitalization
$668M
Total Enterprise Value
$423M
Earnings Per Share
$-0.15
Revenue
$3.96M
Net Profit
$-130M
EBITDA
$-144M
EBITDAMargin
-3,647.4%
Total Debt
$23.7M
Total Equity
$341M
Enterprise Value / Sales
106.97x
TEVNet Income
-3.25x
Debt TEV
0.06x
Investors
Details Hidden

New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements.

Details Hidden

Impresa Management invests in companies located across the globe. The firm targets companies operating in the fields of healthcare therapeutics, medtech, health IT & services, technology, enterprise software, fintech and frontiertech. It provides financing for seed, early & later stage capital requirements.

Details Hidden

Former Co-Founder & CSO at Immunocore Ltd.

Suppliers
Thermo Fisher Scientific, Inc. Computer Software | Waltham, Massachusetts

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment comprises of portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs, and vaccines, as well as diagnosis of disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory on the production line and in the field. The Specialty Diagnostics segment gives diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment involves in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Liberty Property Trust Real Estate Investment Trusts | Malvern, PA

Liberty Property Trust (NYSE:LRY) is a $6.9 billion real estate investment trust which owns 77.8 million square feet of office and industrial space in more than 21 markets throughout the United States and the United Kingdom (as of Sep. 30, 2012). Founded in 1972 and headquartered outside of Philadelphia, Liberty develops, acquires, leases and manages properties with the mission to enhance people's lives through extraordinary work environments. As an extension of this promise, Liberty is one of the nation's leading developers of high-performance green buildings. Liberty's more than 700 office and industrial properties offer exceptional locations, flexible design, thoughtful amenities, cost efficient operations and state-of-the-art technology to the company's 2,300 tenants. Liberty continuously increases the value of its portfolio through expert management, marketing and development

Alpine Immune Sciences, Inc. Hospitals & Patient Services | Seattle, WA

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases; immuno-oncology; and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Competitors
MediGene AG Biotechnology - Martinsried, Germany

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.

Fate Therapeutics, Inc. Biotechnology - San Diego, CA

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Takeda Pharmaceutical Co., Ltd. Pharmaceuticals - Osaka, Japan

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Adaptimmune Therapeutics PLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Adaptimmune Therapeutics PLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Adaptimmune Therapeutics PLC.